Improved RNA-seq of blood-derived RNA increases gene discovery and coverage RNA-seq of blood-derived RNA can aid discovery of the cause of disease, as well as preclinical research. However, the high content of globin mRNA and ribosomal RNA (rRNA) in blood samples limits the detection of rare transcripts and splice variants. The ScriptSeq™ Complete Kit (Blood) is a new method to prepare directional RNA-seq libraries that are virtually free of globin mRNA and rRNA contamination and exhibit high detection of reference and novel genes.
Introduction
Transcriptome analysis by RNA-seq has rapidly become the method of choice for gene-expression profiling as it is not limited to detecting transcripts that correspond to existing genomic sequences. Blood is a particularly attractive sample for disease studies because of its relative ease of collection, unlike tissues, The ability to identify novel genes, splice variants and isoforms is particularly important to discovery, preclinical and clinical research, for which the ultimate goal is to develop a prevention or treatment strategy for over 6,000 rare diseases and 12,000 disease categories. Blood as a sample type, however, presents unique challenges because the collection methods cause fragmentation of the RNA, leading to complications during sample preparation for next-generation sequencing. In addition, as much as 70% of the mRNA in a blood total RNA sample can be globin mRNA, with the remaining total RNA composed of greater than 90% rRNA. Neither globin mRNA nor rRNA contribute high-value RNA-seq information. Removing globin mRNA and rRNA from a blood RNA sample enables deeper sequencing for discovery of rare transcripts and splice variants and reduces the number of expensive sequencing reads that are wasted because they do not lead to prevention or treatment of disease.
Methods overview
The ScriptSeq™ Complete Gold Kit (Blood) is composed of two modules: the Globin-Zero™ module, which removes both rRNA and globin mRNA from the sample, and the ScriptSeq™ v2 library showed >99% depletion of all globin mRNA and rRNA subunits by Globin-Zero™ in both fragmented and intact samples (Fig. 1) . For Method L, depletion of globin mRNA from fragmented samples was insufficient and rRNA was not depleted at all.
More genes detected with Globin-Zero™
One of RNA-seq's greatest strengths is the ability to detect reference and novel genes for the discovery of underlying causes of disease. aligned to the UCSC hg19 annotation using Tophat, and reference and novel genes were detected by Cufflinks. Reference and novel genes are shown combined for a total gene count for each method (Fig. 2) .
Globin-Zero™ detects more reference genes and more novel genes than the older Method L for a combined greater detection of over 360 genes.
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